Argos Therapeutics (OTCMKTS:ARGSQ) is a clinical‐stage biotechnology company focused on the development of personalized immunotherapies for cancer and chronic viral diseases. The company’s proprietary platform harnesses a patient’s own dendritic cells, which are extracted, matured and transfected ex vivo with RNA sequences encoding disease‐specific antigens. Once re‐infused, these engineered cells are designed to elicit a targeted immune response against tumor cells or virally infected tissues.
Argos’s lead program is AGS-003, an autologous dendritic cell vaccine that combines patient‐derived tumor RNA with synthetic CD40L RNA to stimulate T-cell activation. This approach has been studied in renal cell carcinoma and other solid tumors, as well as in chronic hepatitis C infection. By tailoring each dose to the individual’s disease profile, Argos aims to improve specificity and reduce off-target effects compared to conventional therapies.
The company conducts clinical trials across North America and Europe, collaborating with leading cancer centers and research institutes. Manufacturing and quality control operations are based at its Durham, North Carolina facility, which supports scalable production of patient‐specific cell therapies. Argos has also established partnerships with contract research organizations to streamline trial enrollment and data management in multiple geographies.
Founded in 2005 by a team of immunology and biotech veterans, Argos is led by President and Chief Executive Officer William S. Williams, who brings over two decades of experience in biologics development. The executive team includes professionals with backgrounds in clinical operations, regulatory affairs and commercial strategy, reflecting the company’s ambition to advance its pipeline toward regulatory approval and broader patient access.
AI Generated. May Contain Errors.
